CoChat

A Raman Imaging Approach Using CD47 Antibody-Labeled SERS Nanoparticles for Identifying Breast Cancer and Its Potential to Guide Surgical Resection

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Raman spectroscopic imaging has shown great promise for improved cancer detection and localization with the use of tumor targeting surface enhanced Raman scattering (SERS) nanoparticles. With the ultrasensitive detection and multiplexing capabilities that SERS imaging has to offer, scientists have been investigating several clinical applications that could benefit from this unique imaging strategy. Recently, there has been a push to develop new image-guidance tools for surgical resection to help surgeons sensitively and specifically identify tumor margins in real time. We hypothesized that SERS nanoparticles (NPs) topically applied to breast cancer resection margins have the potential to provide real-time feedback on the presence of residual cancer in the resection margins during lumpectomy. Here, we explore the ability of SERS nanoparticles conjugated with a cluster of differentiation-47 (CD47) antibody to target breast cancer. CD47 is a cell surface receptor that has recently been shown to be overexpressed on several solid tumor types. The binding potential of our CD47-labeled SERS nanoparticles was assessed using fluorescence assisted cell sorting (FACS) on seven different human breast cancer cell lines, some of which were triple negative (negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2)). Xenograft mouse models were also used to assess the ability of our Raman imaging system to identify tumor from normal tissue. A ratiometric imaging strategy was used to quantify specific vs. nonspecific probe binding, resulting in improved tumor-to-background ratios. FACS analysis showed that CD47-labeled SERS nanoparticles bound to seven different breast cancer cell lines at levels 12-fold to 70-fold higher than isotype control-labeled nanoparticles (p < 0.01), suggesting that our CD47-targeted nanoparticles actively bind to CD47 on breast cancer cells. In a mouse xenograft model of human breast cancer, topical application of CD47-targeted nanoparticles to excised normal and cancer tissue revealed increased binding of CD47-targeted nanoparticles on tumor relative to normal adjacent tissue. The findings of this study support further investigation and suggest that SERS nanoparticles topically applied to breast cancer could guide more complete surgical resection during lumpectomy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nano8110953

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic illustration of SERS NP conjugation with various elements, including Dylight 650 fluorophore, and PEGylated CD47 antibody.
Figure 1 Schematic illustration of SERS NP conjugation with various elements, including Dylight 650 fluorophore, and PEGylated CD47 antibody.CC BY · PubMed Central
Figure 2 FACS data showing the binding efficiency of fluorescently labeled CD47 antibodies to various cell lines.
Figure 2 FACS data showing the binding efficiency of fluorescently labeled CD47 antibodies to various cell lines.CC BY · PubMed Central
Figure 3 FACS plots showing the fluorescence intensity associated with each cell line tested including: (a) DLD−; (b) DLD+; (c) BT474; (d) BT483; (e) HCC202; (f) MCF7; (g) HCC1806, (h) HCC70; and (i) MDA231. The following experimental groups were tested within each of the cell lines (1) Unstained cells (red), (2) cells incubated with IgG SERS NPs (blue), (3) cells incubated with CD47 antibody (orange), and (4) cells incubated with CD47 SERS NPs (green). FACS was used to assess which cell lines demonstrated significant binding with our CD47 SERS NPs.
Figure 3 FACS plots showing the fluorescence intensity associated with each cell line tested including: (a) DLD−; (b) DLD+; (c) BT474; (d) BT483; (e) HCC202; (f) MCF7; (g) HCC1806, (h) HCC70; and (i) MDA231. The following experimental groups were tested within each of the cell lines (1) Unstained cells (red), (2) cells incubated with IgG SERS NPs (blue), (3) cells incubated with CD47 antibody (orange), and (4) cells incubated with CD47 SERS NPs (green). FACS was used to assess which cell lines demonstrated significant binding with our CD47 SERS NPs.CC BY · PubMed Central
Figure 4 FACS data showing the ratio of CD47 labeled SERS NPs to Isotype IgG labeled SERS NPs. This data reveals the specific binding of our CD47 SERS NPs to each of the cell lines. The Isotype NPs are acting as a control to reveal non-specific binding of the NPs to the cell surface. Note the significant difference (p < 0.01) between the negatively CD47 expressing cell line, DLD−, and the rest of the cell lines.
Figure 4 FACS data showing the ratio of CD47 labeled SERS NPs to Isotype IgG labeled SERS NPs. This data reveals the specific binding of our CD47 SERS NPs to each of the cell lines. The Isotype NPs are acting as a control to reveal non-specific binding of the NPs to the cell surface. Note the significant difference (p < 0.01) between the negatively CD47 expressing cell line, DLD−, and the rest of the cell lines.CC BY · PubMed Central
Figure 5 Quantitative FACS data comparing signal from cells only (blue), cells labeled with an isotype-NP (orange), cells labeled with anti-CD47 mAb (green), and cells labeled with CD47-NP (red).
Figure 5 Quantitative FACS data comparing signal from cells only (blue), cells labeled with an isotype-NP (orange), cells labeled with anti-CD47 mAb (green), and cells labeled with CD47-NP (red).CC BY · PubMed Central
Figure 6 Raman imaging of positive and negative CD47 expressing tissues (DLD+ and DLD−, respectively) harvested from mouse xenograft. (a) Digital photo of excised tissue after NPs administration; (b) Raman imaging of tissue samples; (c) overlay of Raman imaging with tissue sample, notice the increased NP binding in the tissue expressing CD47 as opposed to the negatively CD47 expressing tissue; (d) quantitative ratiometric analysis of specific CD47 SERS NP binding to non-specific Isotype IgG SERS NP binding on tissue samples Notice the significant differences represented by * (p < 0.05) between the positive control (DLD CD47+) and the negative control (DLD CD47−) tissues; error bars represent standard error of mean (SEM). Color bar to the right of Raman images represents Raman intensity, where red represents the highest Raman signal and black represents no associated Raman signal.
Figure 6 Raman imaging of positive and negative CD47 expressing tissues (DLD+ and DLD−, respectively) harvested from mouse xenograft. (a) Digital photo of excised tissue after NPs administration; (b) Raman imaging of tissue samples; (c) overlay of Raman imaging with tissue sample, notice the increased NP binding in the tissue expressing CD47 as opposed to the negatively CD47 expressing tissue; (d) quantitative ratiometric analysis of specific CD47 SERS NP binding to non-specific Isotype IgG SERS NP binding on tissue samples Notice the significant differences represented by * (p < 0.05) between the positive control (DLD CD47+) and the negative control (DLD CD47−) tissues; error bars represent standard error of mean (SEM). Color bar to the right of Raman images represents Raman intensity, where red represents the highest Raman signal and black represents no associated Raman signal.CC BY · PubMed Central
Figure 7 Raman imaging of breast cancer tissues and normal adjacent tissue harvested from mouse xenograft. (a) Digital photo of excised tissue after NPs administration; (b) Raman imaging of tissue samples; (c) overlay of Raman imaging with tissue sample, notice the increased NP binding in the breast cancer tissue as opposed to the normal adjacent tissue; (d) quantitative ratiometric analysis of specific CD47 SERS NP binding to non-specific Isotype IgG SERS NP binding on each of the tissue samples. Notice the significant differences represented by * (p < 0.05) between the cancer tissue and the normal adjacent tissues; error bars represent standard error of mean (SEM). Color bar to the right of Raman images represents Raman intensity, where red represents the highest Raman signal and black represents no associated Raman signal.
Figure 7 Raman imaging of breast cancer tissues and normal adjacent tissue harvested from mouse xenograft. (a) Digital photo of excised tissue after NPs administration; (b) Raman imaging of tissue samples; (c) overlay of Raman imaging with tissue sample, notice the increased NP binding in the breast cancer tissue as opposed to the normal adjacent tissue; (d) quantitative ratiometric analysis of specific CD47 SERS NP binding to non-specific Isotype IgG SERS NP binding on each of the tissue samples. Notice the significant differences represented by * (p < 0.05) between the cancer tissue and the normal adjacent tissues; error bars represent standard error of mean (SEM). Color bar to the right of Raman images represents Raman intensity, where red represents the highest Raman signal and black represents no associated Raman signal.CC BY · PubMed Central
Figure 8 Raman imaging of resected invasive ductal carcinoma specimen from a 55-year-old patient. (a) Digital photo of excised tissue after NPs administration; (b) Raman imaging of tissue sample; (c) quantitative ratiometric analysis of specific CD47 SERS NP binding to non-specific Isotype IgG SERS NP binding on the human tissue sample. Scale bar represents the specific/non-specific binding ratio of our targeted/isotype-labeled nanoparticles.
Figure 8 Raman imaging of resected invasive ductal carcinoma specimen from a 55-year-old patient. (a) Digital photo of excised tissue after NPs administration; (b) Raman imaging of tissue sample; (c) quantitative ratiometric analysis of specific CD47 SERS NP binding to non-specific Isotype IgG SERS NP binding on the human tissue sample. Scale bar represents the specific/non-specific binding ratio of our targeted/isotype-labeled nanoparticles.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 60

Metadata

Authors
Davis, R. M., Campbell, J. L., Burkitt, S., Qiu, Z., Kang, S., Mehraein, M., Miyasato, D., Salinas, H., Liu, J. T. C., & Zavaleta, C.
Affiliations
  • Stanford Medicine (US)
  • University of Southern California (US)
  • Michigan State University (US)
  • University of Washington (US)
Corresponding author
Zavaleta, Cristina
Venue
Nanomaterials
Publisher
MDPI AG
Published
2018-11-20
Volume
8
Issue
11
Pages
953
ISSN
2079-4991 (ISSN-L)
OpenAlex
W2901440549
Cited by
60
References
58
Citations by year
2026: 4 · 2025: 5 · 2024: 12 · 2023: 5 · 2022: 9 · 2021: 12 · 2020: 8 · 2019: 5
FWCI
3.26
Type
journal article
Language
en
Open access
Locations
  • Nanomaterials (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Foundation for the National Institutes of Health (R21CA184608, K22CA160834)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Spectroscopy Techniques in Biomedical and Chemical Research
  • Physical Sciences › Materials Science › Electronic, Optical and Magnetic Materials › Gold and Silver Nanoparticles Synthesis and Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
breast cancer, CD47, Raman imaging, image-guided surgery, surgical resection margin, breast-conserving surgery, tumor targeting, ratiometric imaging, triple-negative breast cancer, xenograft mouse model

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Raman Imaging Approach Using CD47 Antibody-Labeled SERS Nanoparticles for Identifying Breast Cancer and Its Potential to Guide Surgical Resection. https://app.cochat.ai/papers/10.3390/nano8110953
The paper
Davis, R. M., Campbell, J. L., Burkitt, S., Qiu, Z., Kang, S., Mehraein, M., Miyasato, D., Salinas, H., Liu, J. T. C., & Zavaleta, C. (2018). A Raman Imaging Approach Using CD47 Antibody-Labeled SERS Nanoparticles for Identifying Breast Cancer and Its Potential to Guide Surgical Resection. Nanomaterials. https://doi.org/10.3390/nano8110953

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.